DEFA14A ·Filed Apr 22, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor for any unexpected developments in the director elections, though the board's unanimous recommendation suggests routine approval is expected.
Final — all horizons settled through T+60d
ANTX ▲ +12.15% at T+60d
NEUTRAL call +12.15% · α vs SPY +7.13% · entry $4.28 → $4.80
T+1d
+1.40%
call +1.40% · α +0.62%
$4.34
settled 6mo ago
T+5d
+9.35%
call +9.35% · α +7.87%
$4.68
settled 6mo ago
T+20d
+7.24%
call +7.24% · α +2.61%
$4.59
settled 5mo ago
T+60d
+12.15%
call +12.15% · α +7.13%
$4.80
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
AN2 Therapeutics is holding its annual shareholder meeting to elect three Class I directors and ratify the appointment of PricewaterhouseCoopers LLP as its independent auditor. The board recommends voting in favor of all proposals.
Key Financial Metrics
Vote
director election
Meeting
2026-06-03
Key Facts
- Annual meeting scheduled for June 3, 2026
- Three Class I directors up for election: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.
- Proposal to ratify PricewaterhouseCoopers LLP as independent auditor
- Board recommends voting FOR all nominees and FOR the auditor ratification
Financial Impact
No immediate financial impact expected from this routine governance matter
board compositionaudit committee
Risk Factors
- Potential for shareholder dissent on director elections, though unlikely given board recommendation
- Possible concerns about auditor independence, though PricewaterhouseCoopers LLP is a major firm
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-170321 |
| Document: 0001193125-26-170321-index-headers.html | 0001193125-26-170321 |
| Document: 0001193125-26-170321-index.html | 0001193125-26-170321 |
| Document: 0001193125-26-170321.txt | 0001193125-26-170321 |
5 reports for ANTX
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $6.28 | awaiting T+60 | — | $3.63 (−42.20%) |
Jun 4, 2026 20w ago | 8-K | $3.82 $5.55 | ▲ +45.29% | ▲ +41.29% | $3.63 (−4.97%) |
Apr 22, 2026 26w ago | DEFA14A | $4.28 $4.80 | ▲ +12.15% | ▲ +7.13% | $3.63 (−15.19%) |
Apr 21, 2026 26w ago | EFFECT | $3.80 $4.67 | ▲ +22.89% | ▲ +16.00% | $3.63 (−4.47%) |
Apr 20, 2026 27w ago | 424B5 | $3.80 $4.67 | ▼ −22.89% | ▼ −16.00% | $3.63 (+4.47%) |
Showing 5 of 5
US Market Status
Market Closed — Opens Tue (16h 35m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers